TIDMPRTC
PureTech Health PLC
24 October 2019
24 October 2019
PureTech Health plc
PureTech Affiliate Sonde Health Appoints David Liu as CEO
PureTech Health plc (LSE: PRTC) ("PureTech"), a clinical stage
biotechnology company dedicated to discovering, developing and
commercialising highly differentiated medicines for dysfunctions of
the Brain-Immune-Gut (BIG) axis, is pleased to note that its
affiliate Sonde Health has appointed healthcare technology leader
David Liu as chief executive officer and a member of its board of
directors. After over a decade pioneering novel online products
with America Online (AOL), David has served in executive roles in
growth-stage digital health and education enterprises targeting
international markets, including Quartet, an enterprise technology
healthcare company, and Knewton, a leading global education
technology company.
Eric Elenko PhD, chief innovation officer at PureTech said:
"David's experience guiding companies through significant growth
positions him as a valuable addition to Sonde's team as they
pioneer a new approach to healthcare."
The full text of the announcement from Sonde Health is as
follows:
Sonde Health Appoints David Liu as CEO
BOSTON, October 24, 2019 - Sonde Health Inc., a leading company
developing a voice-based technology platform to measure health when
a person speaks, today announced that David Liu has joined Sonde as
chief executive officer and a member of its board of directors.
This appointment follows the recently announced $16 million Series
A financing directed to advance Sonde's capability across multiple
health conditions and device types as well as its commercialisation
activities.
"Sonde Health's vocal biomarker technology has the potential to
fundamentally transform the way we monitor and manage our health
and well-being. David's wealth of experience at the intersection of
healthcare and technology along with his significant executive and
entrepreneurial experience position him perfectly to take Sonde to
the next stage of growth," said Edward Kliphuis, investment
director at M Ventures and board director at Sonde Health. "The
board and I are thrilled to have David lead and further strengthen
Sonde and its talented team."
"A new wave of technology powered by voice is upon us, and its
application in healthcare has already begun to streamline
functional tasks such as researching providers, scheduling
appointments, and updating medical records, " said Mr Liu. "Sonde
is at the forefront of taking voice technology beyond those tasks
to potentially improve people's health outcomes by analysing vocal
biomarkers combined with machine learning. I'm excited to join
Sonde and work with Jim Harper, our co-founder and COO, as we
continue to progress our platform as a fast, reliable, and
non-invasive health check built into widely used smartphone, voice
assisted, and telemedicine technologies."
Sonde's vocal biomarker platform has demonstrated the potential
to effectively detect disease using information obtained from an
individual's voice on commonly-owned devices, such as smartphones
and smart speakers, and it has the potential to fundamentally
change the way mental and physical health is screened and
monitored.
Mr Liu brings a wide range of leadership experiences across
consumer internet, education technology, and digital healthcare to
his role. He most recently served as president and chief operating
officer at Quartet, a growth stage enterprise healthcare technology
company that connects primary care physicians with mental health
providers to improve overall health outcomes for patients and
generate significant savings for payors. Before Quartet, Mr Liu was
president and chief operating officer at Knewton, where - from an
early stage - he helped to build a leading global education
technology company that uses artificial intelligence to personalise
digital learning materials for K-20 students to improve individual
learning outcomes. Mr Liu began his technology career with a decade
at AOL Inc., where he successfully led multiple product areas and
launched the original AOL.com portal as an internal start-up.
Mr Liu recently served as an entrepreneur-in-residence at Weill
Cornell Medicine (WCM), where he evaluated developing technologies
in therapeutics, diagnostics, devices and digital healthcare.
About Sonde Health
Co-founded by PureTech Health (LSE: PRTC), Sonde Health is
developing a voice-based technology platform to measure health when
a person speaks. Sonde's proprietary technology works by sensing
and analysing subtle changes in the voice to create a range of
persistent brain, muscle, and respiratory health measurements that
provide a more complete picture of health in just seconds. To date,
Sonde has collected a leading digital biobank containing millions
of data points comprising voice samples and health metadata from
over 20,000 individuals as part of the ongoing validation of its
platform. Sonde has broad intellectual property coverage worldwide,
currently owning or having exclusive rights to eight patent
applications and three issued patents in five families of patent
filings.
About PureTech
PureTech is a clinical stage biotechnology company dedicated to
discovering, developing and commercialising highly differentiated
medicines for devastating diseases, including intractable cancers,
lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's affiliates, is comprised of 24 product
candidates and one product that has been cleared by the US Food and
Drug Administration (FDA). All of the underlying programmes and
platforms that resulted in this pipeline of product candidates were
initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune, and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, strategies and
expectations regarding Mr Liu's role at Sonde. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks and uncertainties that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks
and uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGGPAUUPBGBW
(END) Dow Jones Newswires
October 24, 2019 02:01 ET (06:01 GMT)
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024